Cargando…

Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review

As the number of people living with type 2 diabetes (T2D) continues to rise, managing their complex needs presents an increasing challenge to physicians. While treatment guidelines provide evidence-based guidance, they are not prescriptive—rather they emphasize individualization of management based...

Descripción completa

Detalles Bibliográficos
Autor principal:	Meece, Jerry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984906/ https://www.ncbi.nlm.nih.gov/pubmed/29574634 http://dx.doi.org/10.1007/s13300-018-0395-3

Ejemplares similares

Review of basal‐plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus
por: Raccah, D., et al.
Publicado: (2017)

Intensification of insulin therapy in patients with type 2 diabetes mellitus: An algorithm for basal-bolus therapy
por: Abrahamson, Martin J., et al.
Publicado: (2012)

Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes
por: Mocarski, Michelle, et al.
Publicado: (2018)

Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study
por: Bellido, Diego, et al.
Publicado: (2018)

Stepwise intensification of insulin therapy in Type 2 diabetes management—exploring the concept of the basal-plus approach in clinical practice
por: Owens, D R
Publicado: (2013)

Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin
por: Buysman, Erin K., et al.
Publicado: (2018)

IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy
por: Freemantle, Nick, et al.
Publicado: (2015)

Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs: When and for whom?
por: Mosenzon, Ofri, et al.
Publicado: (2013)

Initiation and Intensification Strategies in Type 2 Diabetes Management: A Comparison of Basal Plus and Premix Regimens
por: Downie, Michelle, et al.
Publicado: (2016)

Effectiveness and tolerability of treatment intensification to basal–bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study
por: Pfohl, Martin, et al.
Publicado: (2015)

Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin
por: Blonde, Lawrence, et al.
Publicado: (2018)

Therapeutic Inertia and Delays in Insulin Intensification in Type 2 Diabetes: A Literature Review
por: Gavin, James R., et al.
Publicado: (2023)

A 32-Week Randomized Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp 30) Versus Basal–Bolus Therapy in Insulin-Naïve Patients with Type 2 Diabetes
por: Linjawi, Sultan, et al.
Publicado: (2017)

Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets
por: DeVries, J. Hans, et al.
Publicado: (2012)

Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal–Bolus): Exploratory Randomized Trial in Type 2 Diabetes
por: Bebakar, Wan Mohamaed Wan, et al.
Publicado: (2016)

Post-Basal Insulin Intensification and Healthcare Resource Use in Type 2 Diabetes: A Web-Based Physician Survey in the United States and United Kingdom
por: Brod, Meryl, et al.
Publicado: (2019)

Patterns and predictors of antihyperglycemic intensification at hospital discharge for type 2 diabetic patients not on home insulin
por: Abusamaan, Mohammed S., et al.
Publicado: (2020)

Insulin initiation and intensification in patients with T2DM for the primary care physician
por: Unger, Jeff
Publicado: (2011)

Use of glucagon‐like peptide‐1 receptor agonists among individuals on basal insulin requiring treatment intensification
por: Trautmann, M. E., et al.
Publicado: (2018)

Intensification of Insulin Treatment With Insulin Degludec/Aspart in Type 2 Diabetic Patients: A 2-Year Real-World Experience
por: Oner, Hatice, et al.
Publicado: (2022)

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
por: Moreira, Rodrigo Oliveira, et al.
Publicado: (2018)

Detemir as a once-daily basal insulin in type 2 diabetes
por: Nelson, Scott E
Publicado: (2011)

Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes
por: Vargas-Uricoechea, Hernando
Publicado: (2022)

Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial
por: Tinahones, F J, et al.
Publicado: (2014)

Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry
por: Danne, Thomas, et al.
Publicado: (2015)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
por: Lisco, Giuseppe, et al.
Publicado: (2022)

When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study
por: Jang, H C, et al.
Publicado: (2008)

Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist
por: Patel, Dhiren, et al.
Publicado: (2019)

Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial
por: Rojas, Arturo, et al.
Publicado: (2016)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
por: Lau, Ip Tim, et al.
Publicado: (2017)

A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico
por: Garnica-Cuellar, Juan Carlos, et al.
Publicado: (2023)

Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: A Latin American subpopulation analysis of a randomized trial
por: Barbieri, Douglas Eugenio, et al.
Publicado: (2015)

Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co‐formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial
por: Rodbard, H. W., et al.
Publicado: (2016)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care
por: Brunton, Stephen A., et al.
Publicado: (2016)

A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes
por: Edelman, Steven, et al.
Publicado: (2007)

Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
por: Heller, Simon, et al.
Publicado: (2023)

A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes
por: Bain, S., et al.
Publicado: (2019)

Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon‐like peptide‐1 receptor agonist in people with type 2 diabetes
por: Mehta, Roopa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3edlleo27kbqcksv54qtnbos0h